Roberto Abraham Scaruffi

Thursday, 17 March 2016

  
 Editor’s picks March 17th 2016 
 
The Economist
 
This week we have two covers. In Latin America we look forward to Barack Obama’s visit to Cuba. It crowns his gamble that renewed diplomatic relations, frozen for 54 years, will do more than isolation to end the Communist regime and repair the damaged ties between the United States and Latin America

In the rest of the world we analyse Vladimir Putin’s declaration that he is withdrawing from Syria. What seems like a famous victory has a hollow ring. Russia’s foreign campaigns are made-for-TV adventures designed to persuade anxious Russians that their ailing country is once again a force in the world. So where will Mr Putin stage his next drama?

Zanny Minton Beddoes, Editor-in-Chief
 
 
 
The trouble with teamwork
Businesses are embracing the idea of working in teams. The hard task is managing them
READ MORE >
 
Businesses are embracing the idea of working in teams. The hard task is managing them
READ MORE >
 
 
Finance and the blockchain
The hype surrounding distributed ledgers has got financial firms excited. Yet, before blockchains find their niche, first will come a moment of disillusion
READ MORE >
 
 
India’s young people
A new generation of Indians is forsaking fatalism and karma for free will and greater expectations
READ MORE >
 
A new generation of Indians is forsaking fatalism and karma for free will and greater expectations
READ MORE >
 
 
Politics this week
Myanmar’s parliament elected Htin Kyaw as the country’s next president, the first civilian leader after more than 50 years of control by the army. He is close to Aung San Suu Kyi, whose National League for Democracy won elections in November. Miss Suu Kyi is barred by the constitution from taking the job, but says she will be the effective ruler
SEE ARTICLE >
MORE FROM POLITICS THIS WEEK >
 
Business this week
Shares in Valeant, a troubled drugs company, fell by half after it warned of a potential default on some of its $30 billion debt-pile and slashed its outlook. The company came under pressure last year when it jacked up the price of two treatments for heart disease. The Securities and Exchange Commission is looking into a variety of its business practices. Last August Valeant’s stockmarket value was $90 billion; it is now $11 billion
SEE ARTICLE >
MORE FROM BUSINESS THIS WEEK >